# Green Thumb Industries Inc. Unaudited Interim Condensed Consolidated Balance Sheets As of March 31, 2022 and December 31, 2021

(Amounts Expressed in United States Dollars)

		March 31, 2022	December 31, 2021		
			-	(Audited)	
		(in the	ousands)		
ASSETS					
Current Assets:	\$	174,539	\$	230,420	
Cash and Cash Equivalents Accounts Receivable	Φ	27,808	Ф	22,099	
Inventories		109,701		95,471	
Prepaid Expenses		11,102		11,175	
Other Current Assets		5,210		5,065	
Total Current Assets		328,360		364,230	
Property and Equipment, Net		453,114		409,074	
Right of Use Assets, Net		178,193		176,327	
Investments		90,731		94,902	
Investments in Associates		28,202		30,337	
Intangible Assets, Net Goodwill		674,692		675,491	
		640,795		632,849	
Deposits and Other Assets	φ.	3,035	Φ.	2,641	
TOTAL ASSETS	\$	2,397,122	\$	2,385,851	
LIABILITIES AND SHAREHOLDERS' EQUITY					
LIABILITIES					
Current Liabilities:					
Accounts Payable	\$	23,651	\$	14,086	
Accrued Liabilities		77,208		84,724	
Acquisition Consideration Payable		_		31,732	
Compensation Payable		15,055		12,022	
Current Portion of Notes Payable		900		783	
Current Portion of Lease Liabilities		8,947		9,221	
Contingent Consideration Payable		20,592		50,284	
Income Tax Payable		32,831		1,527	
Total Current Liabilities		179,184		204,379	
Long-Term Liabilities:					
Lease Liabilities, Net of Current Portion		186,080		182,539	
Notes Payable, Net of Current Portion and Debt Discount		243,336		239,151	
Contingent Consideration Payable		34,767		33,581	
Warrant Liability		16,948		24,877	
Deferred Income Taxes		81,846		81,846	
TOTAL LIABILITIES		742,161		766,373	
COMMITMENTS AND CONTINGENCIES		· ·		•	
SHAREHOLDERS' EQUITY					
Subordinate Voting Shares (Shares Authorized, Issued and Outstanding at March 31, 2022:					
Unlimited, 203,356,655, and 203,356,655, respectively, at December 31, 2021:					
Unlimited, 201,768,312, and 201,768,312, respectively)		_		_	
Multiple Voting Shares (Shares Authorized, Issued and Outstanding at March 31, 2022:					
Unlimited, 38,531 and 38,531, respectively, at December 31, 2021:					
Unlimited, 38,531 and 38,531, respectively)		_		_	
Super Voting Shares (Shares Authorized, Issued and Outstanding at March 31, 2022:					
Unlimited, 280,031 and 280,031, respectively, at December 31, 2021:					
Unlimited, 285,031 and 285,031, respectively)		_		_	
Share Capital		1,653,703		1,633,672	
Contributed Surplus		5,966		21,245	
Deferred Share Issuances		36,262		36,262	
Accumulated Deficit		(41,124)		(70,063	
Equity of Green Thumb Industries Inc.		1,654,807		1,621,116	
Noncontrolling interests		1,054,007		(1,638	
TOTAL SHAREHOLDERS' EQUITY		1,654,961		1,619,478	
TOTAL SHAREHOLDERS EQUITY TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY	•		\$		
IOTAL LIADILITIES AND SHAREHOLDERS EQUITI	\$	2,397,122	\$	2,385,851	

The accompanying notes are an integral part of these unaudited interim condensed consolidated financial statements

# Green Thumb Industries Inc. Unaudited Interim Condensed Consolidated Statements of Operations Three Months Ended March 31, 2022 and 2021

(Amounts Expressed in United States Dollars, Except Share Amounts)

	Three Months Ended March 31,			Tarch 31,	
		2022		2021	
		(in thousands)			
Revenues, net of discounts	\$	242,600	\$	194,431	
Cost of Goods Sold, net		(119,660)		(83,566)	
Gross Profit		122,940		110,865	
Expenses:		_			
Selling, General, and Administrative		68,388		59,331	
Total Expenses	·	68,388		59,331	
Income From Operations		54,552		51,534	
Other Income (Expense):					
Other Income (Expense), net		11,435		(5,150)	
Interest Income, net		900		50	
Interest Expense, net		(6,070)		(4,123)	
Total Other Income (Expense)		6,265		(9,223)	
Income Before Provision for Income Taxes And Non-Controlling Interest		60,817		42,311	
Provision For Income Taxes		31,131		30,856	
Net Income Before Non-Controlling Interest		29,686		11,455	
Net Income Attributable to Non-Controlling Interest		747		1,086	
Net Income Attributable To Green Thumb Industries Inc.	\$	28,939	\$	10,369	
Net Income per share - basic	\$	0.12	\$	0.05	
Net Income per share - diluted	\$	0.12	\$	0.05	
Weighted average number of shares outstanding - basic		235,838,947		216,210,429	
Weighted average number of shares outstanding - diluted		238,225,420		221,616,157	

The accompanying notes are an integral part of these unaudited interim condensed consolidated financial statements

Green Thumb Industries Inc. Unaudited Interim Condensed Consolidated Statements of Changes in Shareholders' Equity Three Months Ended March 31, 2022 and 2021

(Amounts Expressed in United States Dollars)

	 Share Capital		Contributed Surplus (Deficit)	Deferred Share <u>Issuance</u> (in thou	Accumulated Earnings (Deficit)	Non-Controlling Interest	Total
Balance, January 1, 2021	\$ 1,048,640	\$	4,893 \$	2,587		3,537 \$	914,158
Issuance of shares under business combinations and investments	1,038		(38)	_	_	<u> </u>	1,000
Shares issued as contingent consideration	12,673		_	_	_	_	12,673
Distribution of deferred shares	1,826		_	(1,835)	_	_	(9)
Issuance of registered shares pursuant to Form S-1	155,803		(305)	_	_	_	155,498
Exercise of options, RSUs and warrants	17,008		(11,369)	_	_	_	5,639
Stock-based compensation	_		4,031	_	_	_	4,031
Distributions to third party and limited liability company unit holders	_		_	_	_	(1,675)	(1,675)
Net income	 			<u> </u>	10,369	1,086	11,455
Balance, March 31, 2021	\$ 1,236,988	<b>\$</b> _	(2,788) \$	752	\$ (135,130) \$	2,948 \$	1,102,770
Balance, January 1, 2022	\$ 1,633,672	\$	21,245 \$	36,262 \$	(70,063) \$	(1,638) \$	1,619,478
Noncontrolling interests adjustment for change in ownership	2,379		(17,735)	_	_	15,356	_
Issuance of shares under business combinations and investments	1,406		_	_	_	_	1,406
Shares issued as contingent consideration	13,111		_	_	_	_	13,111
Exercise of options, RSUs and warrants	3,135		(2,195)	_	_	_	940
Stock-based compensation	_		4,651	_	_	_	4,651
Distributions to limited liability company unit holders	_		_	_	_	(14,311)	(14,311)
Net income			_		28,939	747	29,686
Balance, March 31, 2022	\$ 1,653,703	\$	5,966 \$	36,262 \$	(41,124) \$	154 \$	1,654,961

The accompanying notes are an integral part of these unaudited interim condensed consolidated financial statements

# Green Thumb Industries Inc. Unaudited Interim Condensed Consolidated Statements of Cash Flows Three Months Ended March 31, 2022 and 2021

(Amounts Expressed in United States Dollars)

	Three Months Ended March 31,				
		2022		2021	
		(in tho	usands)		
CASH FLOW FROM OPERATING ACTIVITIES					
Net income attributable to Green Thumb Industries Inc.	\$	28,939	\$	10,369	
Net income attributable to non-controlling interest		747		1,086	
Adjustments to reconcile net income to net cash provided by operating activities:					
Depreciation and amortization		22,990		14,994	
Amortization of operating lease assets		9,821		7,751	
Loss on disposal of property and equipment		85		46	
Loss (earnings) on equity method investment		1,203		(623)	
Bad debt expense		117		(74)	
Deferred income taxes				1,690	
Stock-based compensation		4,651		4,031	
Increase in fair value of investments		(4,664)		(392)	
Interest on contingent consideration payable and acquisition liabilities		1,081		_	
(Decrease) increase in fair value of contingent consideration		(16,477)		413	
(Decrease) increase in fair value of warrants		(7,929)		5,851	
Amortization of debt discount		2,279		1,103	
Changes in operating assets and liabilities:					
Accounts receivable		(5,941)		3,256	
Inventories		(13,817)		(2,737)	
Prepaid expenses and other current assets		12		(5,318)	
Deposits and other assets		(395)		(363)	
Accounts payable		9,555		(11,191)	
Accrued liabilities		235		1,755	
Operating lease liabilities		(8,420)		(6,010)	
Income tax payable		31,304		14,019	
NET CASH PROVIDED BY OPERATING ACTIVITIES		55,376		39,656	
CASH FLOW FROM INVESTING ACTIVITIES					
Purchases of property and equipment		(56,831)		(19,422)	
Proceeds from disposal of assets		32		60	
Investments in securities		(5,444)		(6,002)	
Proceeds from sale of investments		160		18,123	
Settlement of acquisition consideration payable		(31,732)		_	
Purchase of businesses, net of cash acquired		(6,586)			
NET CASH USED IN INVESTING ACTIVITIES		(100,401)		(7,241)	
CASH FLOW FROM FINANCING ACTIVITIES					
Distributions to third parties and limited liability company unit holders		(14,311)		(1,675)	
Contributions from unconsolidated subsidiaries		550		350	
Net proceeds from issuance of registered shares pursuant to Form S-1		_		155,498	
Proceeds from exercise of options and warrants		940		5,639	
Proceeds from issuance of notes payable		2,102		_	
Principal repayment of notes payable		(137)		(86)	
NET CASH (USED IN) PROVIDED BY FINANCING ACTIVITIES		(10,856)		159,726	
CASH, CASH EQUIVALENTS AND RESTRICTED CASH:					
NET INCREASE IN CASH AND CASH EQUIVALENTS AND					
RESTRICTED CASH		(55,881)		192,141	
CASH, CASH EQUIVALENTS AND RESTRICTED CASH				·	
BEGINNING OF PERIOD		230,420		83,758	
CASH, CASH EQUIVALENTS AND RESTRICTED CASH END OF					
PERIOD	\$	174,539	•	275,899	

The accompanying notes are an integral part of these unaudited interim condensed consolidated financial statements

# Green Thumb Industries Inc. Unaudited Interim Condensed Consolidated Statements of Cash Flows Three Months Ended March 31, 2022 and 2021

(Amounts Expressed in United States Dollars)

·	Three Months Ended March 31,			
		2022		2021
		(in tho	usands)	
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION				
Interest paid	\$	4,467	\$	3,183
NONCASH INVESTING AND FINANCING ACTIVITIES				
Accrued capital expenditures	\$	(5,366)	\$	(3,406)
Noncash increase in right of use asset	\$	(3,855)	\$	(5,770)
Noncash increase in lease liability	\$	3,855	\$	5,770
Shares issued for purchase of noncontrolling interest	\$	2,379	\$	_
Issuance of shares associated with contingent consideration	\$	13,111	\$	12,673
Deferred share issuances	\$		\$	1,835
Issuance of shares under business combinations	\$	1,406	\$	1,000
Acquisitions				
Inventory	\$	413	\$	_
Accounts receivable		(116)		_
Prepaid assets		72		_
Property and equipment		738		_
Right of use assets		743		_
Identifiable intangible assets		14,143		_
Goodwill		7,946		_
Deposits and other assets		12		_
Liabilities assumed		(466)		_
Lease liabilities		(743)		_
Noncontrolling interests		17,735		_
Equity interests issued		(3,785)		_
Fair value of previously held equity interest		(14,500)		_
Deferred cash		(250)		_
Settlement of noncontrolling interests		(15,356)		_
	\$	6,586	\$	_
ADDITIONAL SUPPLEMENTAL INFORMATION				
Decrease (increase) in fair value of investments	\$	9,455		(392)
Increase in fair value of equity method investments		(14,119)		
TOTAL INCREASE IN FAIR VALUE OF INVESTMENTS	\$	(4,664)	\$	(392)

The accompanying notes are an integral part of these unaudited interim condensed consolidated financial statements

#### Notes to Unaudited Interim Condensed Consolidated Financial Statements

(Amounts Expressed in United States Dollars, Except Where Stated Otherwise)

# 1. Overview and Basis of Presentation

#### (a) Description of Business

Green Thumb Industries Inc. ("Green Thumb" or the "Company"), a national cannabis consumer packaged goods company and retailer, promotes well-being through the power of cannabis while being committed to community and sustainable, profitable growth. Green Thumb owns, manufactures, and distributes a portfolio of cannabis consumer packaged goods brands including Beboe, Dogwalkers, Dr. Solomon's, Good Green, incredibles, and RYTHM, to third-party retail stores across the United States as well as to Green Thumb owned retail cannabis stores. The Company also owns and operates retail cannabis stores that include a rapidly growing national chain named RISE, which sell our products and third-party products. As of March 31, 2022, Green Thumb has operations in fifteen markets (California, Colorado, Connecticut, Florida, Illinois, Maryland, Massachusetts, Minnesota, Nevada, New Jersey, New York, Ohio, Pennsylvania, Rhode Island and Virginia), employs approximately 4,000 people and serves hundreds of thousands of patients and customers annually.

The Company's registered office is located at 250 Howe Street, 20<sup>th</sup> Floor, Vancouver, British Columbia, V6C 3R8. The Company's U.S. headquarters are at 325 W. Huron St., Suite 700, Chicago, IL 60654.

#### (b) Basis of Presentation

The accompanying unaudited interim condensed consolidated financial statements include the accounts of Green Thumb and have been prepared in accordance with accounting principles generally accepted in the United States ("GAAP") for interim financial information and in accordance with the rules and regulations of the U.S. Securities & Exchange Commission ("SEC"). Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements and, accordingly, certain information, footnotes and disclosures normally included in the annual financial statements, prepared in accordance with GAAP, have been condensed or omitted in accordance with SEC rules and regulations. The financial data presented herein should be read in conjunction with the audited consolidated financial statements and accompanying notes included in the Company's Annual Report on Form 10-K for the year ended December 31, 2021, as amended (the "2021 Form 10-K"). In the opinion of management, the financial data presented includes all adjustments necessary to present fairly the financial position, results of operations and cash flows for the interim periods presented. Certain previously reported amounts have been reclassified between line items to conform to the current period presentation. Results of interim periods should not be considered indicative of the results for the full year. These unaudited interim condensed consolidated financial statements include estimates and assumptions of management that affect the amounts reported in the unaudited condensed consolidated financial statements. Actual results could differ from these estimates.

# (c) Significant Accounting Policies

There have been no changes to the Company's significant accounting policies as described in Note 2 of the 2021 Form 10-K.

# (d) Earnings per Share

Basic earnings per share is calculated using the treasury stock method, by dividing the net earnings attributable to shareholders by the weighted average number of common shares outstanding during each of the periods presented. Contingently issuable shares (including shares held in escrow) are not considered outstanding common shares and consequently are not included in the earnings per share calculation. Diluted earnings per share is calculated using the treasury stock method by adjusting the weighted average number of common shares outstanding to assume conversion of all dilutive potential common shares. The Company has three categories of potentially dilutive common share equivalents: restricted stock units, stock options and warrants. As of March 31, 2022, the Company had 5,340,863 options, 306,724 restricted stock units and 3,835,278 warrants outstanding. As of March 31, 2021, the Company had 5,299,440 options, 592,535 restricted stock units and 2,294,523 warrants outstanding.

#### Notes to Unaudited Interim Condensed Consolidated Financial Statements

(Amounts Expressed in United States Dollars, Except Where Stated Otherwise)

## 1. Overview and Basis of Presentation (Continued)

# (d) Earnings per Share (Continued)

In order to determine diluted earnings per share, it is assumed that any proceeds from the vesting of dilutive unvested restricted stock units, or exercise of unvested stock options and warrants would be used to repurchase common shares at the average market price during the period. Under the treasury stock method, the diluted earnings per share calculation excludes any potential conversion of stock options and convertible debt that would increase earnings per share or decrease loss per share. For the three months ended March 31, 2022, the computation of diluted earnings per share included 1,699,469 options, 183,763 restricted stock units and 503,241 warrants. For the three months ended March 31, 2021, the computation of diluted earnings per share included 3,702,372 options, 431,220 restricted stock units and 1,272,136 warrants. For the three months ended March 31, 2022 and 2021, the weighted average number of anti-dilutive stock options excluded from the computation of diluted earnings per share were 842,033 and 23,887, respectively.

# (e) Recently Adopted Accounting Standards

In August 2020, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Updated ("ASU") 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity's Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity's Own Equity, to improve financial reporting associated with accounting for convertible instruments and contracts in an entity's own equity. The amendments in this update are effective for public business entities for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. The Company adopted ASU 2020-06 on January 1, 2022. The adoption of the standard did not have a material impact on the Company's unaudited interim condensed consolidated financial statements.

# (f) Recently Issued Accounting Standards

The Company reviews recently issued accounting standards on a quarterly basis and has determined there are no standards yet to be adopted which are relevant to the business for disclosure.

# (g) Coronavirus Pandemic

In March 2020, the World Health Organization categorized coronavirus disease 2019 (together with its variants, "COVID-19") as a pandemic. COVID-19 continues to spread throughout the U.S. and other countries across the world, and the duration and severity of its effects are currently unknown. The Company continues to implement and evaluate actions to strengthen its financial position and support the continuity of its business and operations.

The Company's unaudited interim condensed consolidated financial statements presented herein reflect estimates and assumptions made by management that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited interim condensed consolidated financial statements and reported amounts of revenue and expenses during the periods presented. Such estimates and assumptions affect, among other things, the Company's goodwill; long-lived assets and intangible assets; operating lease right of use assets and operating lease liabilities; valuation of deferred income taxes; the allowance for doubtful accounts; assessment of the Company's lease and non-lease contract expenses; and measurement of compensation cost for bonus and other compensation plans. While the Company's revenue, gross profit and operating income were not impacted during the first three months of 2022, the uncertain nature of the spread of COVID-19 and the uncertainty of the impact of nationwide vaccine programs may impact the Company's business operations for reasons including the potential quarantine of the Company's employees or those of its supply chain partners.

(Amounts Expressed in United States Dollars, Except Where Stated Otherwise)

#### 2. INVENTORIES

The Company's inventories include the following at March 31, 2022 and December 31, 2021:

	March 31, 2022	December 31, 2021
	(in thousa	nds)
Raw Material	\$ 5,297 \$	5,278
Packaging and Miscellaneous	10,576	8,622
Work in Process	44,112	42,403
Finished Goods	52,462	41,069
Reserve for Obsolete Inventory	(2,746)	(1,901)
<b>Total Inventories</b>	\$ 109,701 \$	95,471

# 3. PROPERTY AND EQUIPMENT

At March 31, 2022 and December 31, 2021, property and equipment consisted of the following:

	 March 31, 2022	December 31, 2021			
	(in thousands)				
Buildings and Improvements	\$ 114,946 \$	101,283			
Equipment, Computers and Furniture	96,935	83,281			
Leasehold Improvements	126,092	114,303			
Land Improvements	607	607			
Capitalized Interest	8,281	6,523			
<b>Total Property and Equipment</b>	 346,861	305,997			
Less: Accumulated Depreciation	(53,175)	(45,198)			
Property and Equipment, net	293,686	260,799			
Land	20,258	20,258			
Assets Under Construction	139,170	128,017			
Property and Equipment, net	\$ 453,114 \$	409,074			

Assets under construction represent construction in progress related to both cultivation and dispensary facilities not yet completed or otherwise not ready for use.

Depreciation expense for the three months ended March 31, 2022 totaled \$8,048 thousand, of which \$5,046 thousand, is included in cost of goods sold. Depreciation expense for the three months ended March 31, 2021 totaled \$4,767 thousand, of which \$2,869 thousand, is included in cost of goods sold.

(Amounts Expressed in United States Dollars, Except Where Stated Otherwise)

#### 4. ACQUISITIONS

The Company has determined that the below acquisitions are business combinations under Accounting Standards Codification ("ASC") 805, *Business Combinations*. They are accounted for by applying the acquisition method, whereby the assets acquired and the liabilities assumed are recorded at their fair values with any excess of the aggregate consideration over the fair values of the identifiable net assets allocated to goodwill. Operating results have been included in these unaudited interim condensed consolidated financial statements from the date of the acquisition. Supplemental pro forma financial information has not been presented as the impact was not material to the Company's consolidated financial statements. The goodwill recorded primarily includes the expected synergies resulting from combining the operations of the acquired entity with those of the Company.

# (a) Acquisition of ILDISP, LLC

On March 1, 2022, the Company acquired the remaining 50% ownership interests of ILDISP, LLC ("ILDISP") from the Company's former membership interest partner for the purposes of expanding the Company's operational capacity in the Illinois market. Prior to March 1, 2022, one of the two dispensaries owned by ILDISP, RISE Effingham, was consolidated by Green Thumb as the Company was determined to be the primary beneficiary of the variable interest entity. The other retail dispensary was accounted for as an equity method investment given the Company's 50% ownership interest, and its ability to significantly influence the dispensaries operations.

The total consideration exchanged included \$18,868 thousand in cash, which included \$250 thousand in deferred consideration, along with 204,036 Subordinate Voting Shares valued at \$3,785 thousand, based on the fair value of the securities on their date of issuance, which was the closing price of Green Thumb's Subordinate Voting Shares as traded on the Canadian Securities Exchange ("CSE") on the date of the transaction.

The Company allocated the total consideration exchanged to each of the acquired retail dispensaries. Accordingly, the consideration allocated to RISE Effingham was approximately \$11,857 thousand in cash along with 128,217 Subordinate Voting Shares of Green Thumb that had a fair value of \$2,379 thousand. The remaining equity associated with the Company's purchase of the noncontrolling interest was closed to contributed surplus (deficit) of Green Thumb as of March 1, 2022.

The equity method investment associated with the other dispensary owned by ILDISP was remeasured at fair value of \$14,500 thousand as of the date of the transaction, and resulted in a gain on the fair value of the equity method investment of \$14,119 thousand, which was recorded in other income (expense) on the unaudited interim condensed consolidated statement of operations. In addition, the Company allocated consideration of \$7,011 thousand in cash along with 75,818 Subordinate Voting Shares of Green Thumb, with a fair value of \$1,406 thousand. After completing the preliminary allocation of the aggregate consideration exchanged for the assets acquired and liabilities assumed, the Company recorded a license intangible asset of \$14,143 thousand and non-tax deductible goodwill of \$7,956 thousand. The weighted average amortization period for the license intangible was 15 years. Acquisition related expenses associated with the transaction were not material.

The preliminary valuation was based on management's estimates and assumptions which are subject to change within the purchase price allocation period (generally one year from the acquisition date). The primary areas of the purchase price allocation that are not yet finalized relate to the valuation of the intangible asset acquired, the previously held equity method investment, and the residual goodwill.

#### Notes to Unaudited Interim Condensed Consolidated Financial Statements

(Amounts Expressed in United States Dollars, Except Where Stated Otherwise)

# 5. INTANGIBLE ASSETS AND GOODWILL

# (a) Intangible Assets

Intangible assets are recorded at cost less accumulated amortization and impairment losses, if any. Intangible assets acquired in a business combination are measured at fair value at the acquisition date. Amortization of definite life intangibles is provided on a straight-line basis over their estimated useful lives. The estimated useful lives, residual values, and amortization methods are reviewed at each year end, and any changes in estimates are accounted for prospectively.

At March 31, 2022 and December 31, 2021, intangible assets consisted of the following:

	_	March 31, 2022				December 31, 2021				
	_	Gross Carrying Amount	Accumulated Amortization		Net Book Value		Gross Carrying Amount	Accumulated Amortization		Net Book Value
	_		(in thousands)					(in thousands)		
Licenses and Permits	\$	670,043 \$	80,835	\$	589,208	\$	655,900 \$	69,812	\$	586,088
Trademarks		98,936	28,017		70,919		98,936	25,096		73,840
Customer Relationships		24,438	10,817		13,621		24,438	9,944		14,494
Non-Competition Agreements		2,565	1,621		944		2,565	1,496		1,069
Total Intangible Assets	\$	795,982 \$	121,290	\$	674,692	\$	781,839 \$	106,348	\$	675,491

The Company recorded amortization expense for the three months ended March 31, 2022 and 2021 of \$14,942 thousand and \$10,227 thousand, respectively.

The following table outlines the estimated annual amortization expense related to intangible assets as of March 31, 2022:

		Estimated Amortization
Year Ending December 31,		(in thousands)
Remainder of 2022	\$	45,291
2023		60,388
2024		59,807
2025		59,709
2026		51,697
2027 and Thereafter		397,800
	s <u> </u>	674,692

As of March 31, 2022, the weighted average amortization period remaining for intangible assets was 12.55 years.

# (b) Goodwill

At March 31, 2022 and December 31, 2021 the balances of goodwill, by segment, consisted of the following:

	_	Retail	<b>Consumer Package Goods</b>	Total
			(in thousands)	
As of December 31, 2021	\$	274,811 \$	358,038 \$	632,849
Acquisition of ILDISP, LLC		7,956	<u> </u>	7,956
Adjustments to Purchase Price Allocations		157	(167)	(10)
As of March 31, 2022	\$	282,924 \$	357,871 \$	640,795

(Amounts Expressed in United States Dollars, Except Where Stated Otherwise)

#### 6. INVESTMENTS

As of March 31, 2022 and December 31, 2021, the Company held various equity interests in cannabis companies as well as investments in convertible notes that had a combined fair value of \$90,731 thousand and \$94,902 thousand as of each period end, respectively. The Company measures its investments that do not have readily determinable fair value at cost minus impairment, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer. The Company performs an assessment on a quarterly basis to determine whether triggering events for impairment exist and to identify any observable price changes.

The following table summarizes the changes in the Company's investments during the three months ended March 31, 2022 and year ending December 31, 2021:

	_	March 31, 2022	<b>December 31, 2021</b>
		(in tho	usands)
Beginning	\$	94,902	\$ 40,795
Additions		5,444	83,689
Disposals		(160)	(18,417)
Fair value adjustment		(9,455)	6,377
Transfers out		_	(17,542)
Ending	\$ _	90,731	\$ 94,902

During the three months ended March 31, 2022, the Company recorded fair value gains (losses) of \$(9,455) thousand, of which \$(9,609) thousand was recorded within other income (expense) and \$154 thousand relates to various note receivable investments and was recorded to interest income on the unaudited interim condensed consolidated statement of operations.

# (a) Equity Investments

As of March 31, 2022 and December 31, 2021, the Company held equity investments in publicly traded entities which have readily determinable fair values, which are classified as Level 1 investments, of \$12,527 thousand and \$20,583 thousand, respectively. During the three months ended March 31, 2022 and the three months ended March 31, 2021, the Company recorded net gains (losses) on the change in fair value of such investments of \$(7,897) thousand and \$268 thousand, respectively, within other income (expense) on the consolidated statement of operations. The Company received proceeds from the sale of such investments of \$160 thousand and \$18,123 thousand, respectively. These investments are classified as trading securities on the Company's unaudited interim condensed consolidated balance sheets.

As of March 31, 2022 and December 31, 2021, the Company held equity investments in privately held entities that did not have readily determinable fair values, which are classified as Level 3 investments, of \$42,309 thousand and \$33,066 thousand, respectively. During the three months ended March 31, 2022 and the three months ended March 31, 2021, the Company recorded net gains (losses) on the change in fair value of such investments of \$455 thousand and \$124 thousand, respectively, within other income (expense) on the consolidated statement of operations. There were no sales of these investments during these periods. These investments are classified as trading securities on the Company's unaudited interim condensed consolidated balance sheets.

See Note 14 - Fair Value Measurements for additional details.

Unrealized gains and (losses) recognized on equity investments held during the three months ended March 31, 2022 and 2021 were \$(9,477) thousand and \$251 thousand, respectively.

(Amounts Expressed in United States Dollars, Except Where Stated Otherwise)

#### **6. INVESTMENTS** (Continued)

# (b) Convertible Notes Receivable

During the three months ended March 31, 2022 and year ended December 31, 2021, the Company made multiple investments in various note receivable instruments, including note receivable instruments with conversion features.

As of March 31, 2022 and December 31, 2021, the Company held note receivable instruments, which were classified as a Level 1 investment as they represent public debt of a publicly traded entity, and had a fair value of \$23,257 thousand and \$23,534 thousand, respectively. During the three months ended March 31, 2022, the Company recorded net gains (losses) on the change in fair value of such investments of \$(276) thousand within other income (expense) on the consolidated statement of operations. There were no gains or (losses) recognized on these investments during the three months ended March 31, 2021. The note receivable instruments had a stated interest rate of 13% and a maturity date of April 29, 2025. These notes did not contain conversion features and are currently classified as trading securities on the Company's unaudited interim condensed consolidated balance sheets.

As of March 31, 2022 and December 31, 2021, the Company held note receivable instruments which were classified as Level 3 investments as they represent loans provided to privately held entities that do not have readily determinable fair values. The note receivable instruments had a combined fair value of \$12,638 thousand and \$17,719 thousand, respectively, with stated interest ranging between 0.91% - 10% and terms between 15 months to five years. During the three months ended March 31, 2022, the Company recorded net gains (losses) on the change in fair value of such investments of \$(1,891) thousand within other income (expense) on the consolidated statement of operations. There were no gains or (losses) recognized on these investments during the three months ended March 31, 2021. The combined fair value amounts include the initial investment cost and combined contractual accrued interest of \$154 thousand. These notes are classified as trading securities on the Company's unaudited interim condensed consolidated balance sheets.

See Note 14 - Fair Value Measurements for additional details.

(Amounts Expressed in United States Dollars, Except Where Stated Otherwise)

#### 7. LEASES

### (a) Operating Leases

The Company has operating leases for its retail dispensaries and processing and cultivation facilities located throughout the U.S, as well as for corporate office space located in Illinois. Operating lease right-of-use assets and operating lease liabilities are recognized based on the present value of future minimum lease payments over the lease term at commencement date.

All real estate leases are recorded on the balance sheet. Equipment and other non-real estate leases with an initial term of twelve months or less are not recorded on the balance sheet. Lease agreements for some locations provide for rent escalations and renewal options. Certain real estate leases require payment for fixed and variable non-lease components, such as taxes, insurance and maintenance. The Company accounts for each real estate lease and the related non-lease components together as a single component.

The Company determines if an arrangement is a lease at inception. The Company must consider whether the contract conveys the right to control the use of an identified asset. Certain arrangements require significant judgment to determine if an asset is specified in the contract and if the Company directs how and for what purpose the asset is used during the term of the contract. For the three months ended March 31, 2022, the company recorded operating lease expense of \$9,821 thousand compared to operating lease expense of \$7,751 thousand for the three months ended March 31, 2021.

Other information related to operating leases as of March 31, 2022 and December 31, 2021 were as follows:

	March 31, 2022	December 31, 2021
Weighted average remaining lease term (years)	11.48	11.82
Weighted average discount rate	13.53%	13.60%

Maturities of lease liabilities for operating leases as of March 31, 2022 were as follows:

	_	Maturities of Lease Liability				
Year Ending December 31,		Third Party	Related Party	Total		
			(in thousands)			
Remainder of 2022	\$	25,476 \$	843	\$ 26,319		
2023		33,868	1,144	35,012		
2024		33,304	1,027	34,331		
2025		30,880	948	31,828		
2026		28,947	970	29,917		
2027 and Thereafter		274,862	7,066	281,928		
Total Lease Payments		427,337	11,998	439,335		
Less: Interest		(238,809)	(5,499)	(244,308)		
Present Value of Lease Liability	\$	188,528 \$	6,499	\$ 195,027		

#### (b) Related Party Operating Leases

The Company entered into related party transactions with respect to its leasing arrangements for certain facilities in Florida, Maryland, Massachusetts and Nevada. Wendy Berger, a director of the Company, is a principal of WBS Equities, LLC, which is the Manager of Mosaic Real Estate, LLC, and owns the facilities leased by the Company. Additionally, Mosaic Real Estate, LLC is indirectly owned in part by Ms. Berger (through the Wendy Berger 1998 Revocable Trust), Benjamin Kovler, the Chief Executive Officer and a director of the Company (through KP Capital, LLC), and Anthony Georgiadis, the Chief Financial Officer and a director of the Company (through Three One Four Holdings, LLC). The terms of these leases range from 7 years to 15 years. For the three months ended March 31, 2022 and 2021, the Company recorded lease expense of \$295 thousand in each period, associated with these leasing arrangements.

(Amounts Expressed in United States Dollars, Except Where Stated Otherwise)

# 8. NOTES PAYABLE

At March 31, 2022 and December 31, 2021, notes payable consisted of the following:

	N	Iarch 31, 2022	<b>December 31, 2021</b>
		(in thousands	s)
Charitable Contributions <sup>1</sup>	\$	1,190 \$	1,238
Private placement debt dated April 30, 2021 <sup>2</sup>		230,966	228,690
Mortgage notes <sup>3</sup>		12,080	10,006
Total notes payable		244,236	239,934
Less: current portion of notes payable		(900)	(783)
Notes payable, net of current portion	\$	243,336 \$	239,151

<sup>&</sup>lt;sup>1</sup> In connection with acquisitions completed in 2017 and 2019, the Company is required to make quarterly charitable contributions of \$50 thousand through October 2024 and annual charitable contributions of \$250 thousand through May 2024, respectively. The net present value of these required payments has been recorded as a liability with interest rates ranging between 2.17% - 7.00%.

### (a) Related Parties

A portion of the April 30, 2021 Notes are held by related parties as well as unrelated third-party lenders at a percentage of approximately 1% and 99%, respectively. The related parties consist of Benjamin Kovler, the Chief Executive Officer and Chairman of the Company (held through KP Capital, LLC and Outsiders Capital, LLC); Andrew Grossman, the Executive Vice President of Capital Markets of the Company (held through AG Funding Group, LLC); Anthony Georgiadis, the Chief Financial Officer and a director of the Corporation (held through Three One Four Holdings, LLC); and Anthony Georgiadis and William Gruver, a director of the Corporation (held through ABG, LLC).

<sup>&</sup>lt;sup>2</sup> The April 30, 2021 private placement debt was issued in an original amount of \$249,934 thousand with an interest rate of 7.00%, maturing on April 30, 2024. The debt was issued at a discount, the carrying value of which was \$18,968 thousand and \$21,244 thousand as of March 31, 2022 and December 31, 2021, respectively.

<sup>&</sup>lt;sup>3</sup> Mortgage notes in the original amount of \$12,597 thousand and \$10,437 thousand as of March 31, 2022 and December 31, 2021, respectively, were issued by the Company in connection with various operating properties. These mortgage notes mature between August 20, 2025 and June 5, 2035 and were issued at a discount, the carrying value of which was \$159 thousand and \$162 thousand, respectively, and are presented net of principal payments of \$358 thousand and \$269 thousand as of March 31, 2022 and December 31, 2021, respectively.

(Amounts Expressed in United States Dollars, Except Where Stated Otherwise)

#### 9. WARRANTS

As part of the Company's private placement financing, as well as other financing arrangements, the Company issued warrants to related parties, as well as unrelated third parties, which allow the holders to purchase Subordinate Voting Shares at an exercise price determined at the time of issuance.

The following table summarizes the number of warrants outstanding as of March 31, 2022 and December 31, 2021:

	Lia	Liability Classified			Equity Classified			
						Weighted		
		Weighted	Weighted		Weighted	Average		
		Average	Average		Average	Remaining		
	Number of	Exercise	Remaining	Number of	Exercise	Contractual		
	Shares	Price (C\$)	Contractual Life	Shares	Price (USD)	Life		
Balance as of December 31, 2021	2,097,931 C\$	18.26	2.42	1,737,347	\$ 31.83	4.38		
Balance as of March 31, 2022	2,097,931 C\$	18.26	2.17	1,737,347	\$ 31.83	4.13		

# (a) Liability Classified Warrants Outstanding

The following table summarizes the fair value of the liability classified warrants at March 31, 2022 and December 31, 2021:

				Fair Value	
Warrant Liability	Strike Price	Warrants Outstanding	March 31, 2022	December 31, 2021	 Change
				(in thousands)	
Bridge Financing Warrants Issued April 2019	C\$22.90	100,723	\$ 336	\$ 676	\$ (340)
Private Placement Financing Warrants Issued May 2019	C\$19.39	1,606,533	12,359	18,527	(6,168)
Modification Warrants Issued November 2019	C\$12.04	316,947	3,442	4,603	(1,161)
Additional Modification Warrants Issued May 2020	C\$14.03	73,728	811	1,071	(260)
Totals		2,097,931	\$ 16,948	\$ 24,877	\$ (7,929)

During the three months ended March 31, 2022 and 2021, the Company recorded a gain of \$7,929 thousand and a loss of \$5,851 thousand, respectively, on the change in the fair value of the warrant liability within other income (expense) on the unaudited interim condensed consolidated statements of operations.

The following table summarizes the significant assumptions used in determining the fair value of the warrant liability as of each reporting date (see Note 14 - Fair Value Measurements for additional details):

	March 31,	December 31,
Significant Assumptions	2022	2021
Volatility	65.5% - 69.83%	59.95% - 74.04%
Remaining Term	0.53 - 3.15 years	0.78 - 3.39 years
Risk Free Rate	2.17% - 2.28%	0.91% - 1.06%

# Notes to Unaudited Interim Condensed Consolidated Financial Statements

(Amounts Expressed in United States Dollars, Except Where Stated Otherwise)

# 9. WARRANTS (Continued)

# (b) Equity Classified Warrants Outstanding

The following table summarizes the fair value of the equity classified warrants at March 31, 2022 and December 31, 2021:

				Fair	Value	
Warrants Included in Contributed Surplus	Stri	ke Price	Warrants Outstanding	arch 31, 2022		mber 31, 2021
				(in tho	usands)	
Mortgage Warrants Issued June 2020	\$	9.10	35,000	\$ 181	\$	181
Private Placement Refinance Warrants Issued April 2021	\$	32.68	1,459,044	22,259		22,259
Private Placement Refinance Warrants Issued October 2021	\$	30.02	243,303	2,616		2,616
Totals			1,737,347	\$ 25,056	\$	25,056

The equity warrants were valued as of the date of issuance using a Black Scholes Option Pricing model. The following table summarizes the significant assumptions used in determining the fair value of the warrants as of each respective issuance date:

Significant Assumptions	Private Placement Refinancing Warrants	Private Placement Refinancing Warrants	Dispensary Mortgage Warrants
Date of Issuance	October 15, 2021	April 30, 2021	June 5, 2020
Volatility	73%	73%	80%
Estimated Term	4 years	4 years	5 years
Risk Free Rate	1.12%	0.74%	0.37%

#### Notes to Unaudited Interim Condensed Consolidated Financial Statements

(Amounts Expressed in United States Dollars, Except Where Stated Otherwise)

#### 10. SHARE CAPITAL

Common shares, which include the Company's Subordinate Voting Shares, Multiple Voting Shares and Super Voting Shares, are classified as equity. Incremental costs directly attributable to the issuance of common shares are recognized as a deduction from equity. The proceeds from the exercise of stock options or warrants together with amounts previously recorded in reserves over the applicable vesting periods are recorded as share capital. Income tax relating to transaction costs of an equity transaction is accounted for in accordance with ASC 740, *Income Taxes*.

# (a) Authorized

The Company has the following classes of share capital, with each class having no par value:

# (i) Subordinate Voting Shares

The holders of the Subordinate Voting Shares are entitled to receive dividends which may be declared from time to time and are entitled to one vote per share at meetings of the Company's shareholders. All Subordinate Voting Shares are ranked equally with regard to the Company's residual assets. The Company is authorized to issue an unlimited number of no par value Subordinate Voting Shares. During the three months ended March 31, 2022, the shareholders of the Company converted 5,000 Multiple Voting Shares into 500,000 Subordinate Voting Shares.

### (ii) Multiple Voting Shares

Each Multiple Voting Share is entitled to 100 votes per share at shareholder meetings of the Company and is exchangeable for 100 Subordinate Voting Shares. At March 31, 2022, the Company had 38,531 issued and outstanding Multiple Voting Shares, which convert into 3,853,100 Subordinate Voting Shares. The Company is authorized to issue an unlimited number of Multiple Voting Shares. During the three months ended March 31, 2022, the shareholders of the Company converted 5,000 Multiple Voting Shares into 500,000 Subordinate Voting Shares.

# (iii) Super Voting Shares

Each Super Voting Share is entitled to 1,000 votes per share at shareholder meetings of the Company and is exchangeable for 100 Subordinate Voting Shares or one Multiple Voting Share. At March 31, 2022, the Company had 280,031 issued and outstanding Super Voting Shares which convert into 28,003,100 Subordinate Voting Shares. The Company is authorized to issue an unlimited number of Super Voting Shares. During the three months ended March 31, 2022, the shareholders of the Company converted 5,000 Super Voting Shares into 5,000 Multiple Voting Shares.

# (b) Issued and Outstanding

A reconciliation of the beginning and ending amounts of the issued and outstanding shares by class is as follows:

	Issued and Outstanding				
	Subordinate Voting Shares	Multiple Voting Shares	Super Voting Shares		
As of December 31, 2021	201,768,312	38,531	285,031		
Issuance of shares under business combinations and					
investments	204,036	_	_		
Distribution of contingent consideration	667,080	_			
Issuance of shares upon exercise of options and					
warrants	109,582	_	_		
Issuances of shares upon vesting of RSUs	107,645	_			
Exchange of shares	500,000		(5,000)		
As of March 31, 2022	203,356,655	38,531	280,031		

#### Notes to Unaudited Interim Condensed Consolidated Financial Statements

(Amounts Expressed in United States Dollars, Except Where Stated Otherwise)

#### 10. SHARE CAPITAL (Continued)

#### (b) Issued and Outstanding (Continued)

# (i) Issuance of Shares Under Business Combinations and Investments

ILDISP, LLC

On March 1, 2022, the Company issued 204,036 Subordinate Voting Shares with a value of approximately \$3,785 thousand, based on a 20 consecutive day volume weighted average price ("VWAP"), in connection with the Company's acquisition of two Illinois-based dispensaries. The shares issued resulted in an increase in share capital and a corresponding increase in the net assets acquired. See Note 4 - Acquisitions for additional details.

# (ii) Distribution of Contingent Consideration

Dharma Pharmaceuticals, LLC

In connection with the Company's 2021 acquisition of Dharma Pharmaceuticals, LLC ("Dharma"), the purchase agreement included contingent consideration of up to \$65,000 thousand in Subordinate Voting Shares of Green Thumb, dependent upon the successful opening of up to 5 retail dispensaries in the Virginia area within the first three years following the signing of the agreement and the legal sale of adult use cannabis in a retail dispensary by January 1, 2025. On February 25, 2022, the Company issued 667,080 Subordinate Voting Shares to the former owners of Dharma in connection with the successful opening of two retail dispensaries in Virginia. The shares had a fair value of \$13,111 thousand at the date of issuance.

As of March 31, 2022 and December 31, 2021, the estimated fair value of the contingent consideration associated with the acquisition of Dharma, which was valued based on a probability weighting of the potential payments, was \$39,137 thousand and \$48,665 thousand, respectively. As of March 31, 2022 and December 31, 2021, \$10,692 thousand and \$20,884 thousand, respectively, was included as a current liability on the Company's unaudited interim condensed consolidated balance sheets.

# (c) Stock-Based Compensation

The Company operates equity settled stock-based remuneration plans for its eligible directors, officers, employees and consultants. All goods and services received in exchange for the grant of any stock-based payments are measured at their fair value unless the fair value cannot be estimated reliably. If the Company cannot estimate reliably the fair value of the goods and services received, the Company measures their value indirectly by reference to the fair value of the equity instruments granted. For transactions with employees and others providing similar services, the Company measures the fair value of the services by reference to the fair value of the equity instruments granted. Equity settled stock-based payments under stock-based payment plans are ultimately recognized as an expense in profit or loss with a corresponding credit to equity.

In June 2018, the Company established the Green Thumb Industries Inc. 2018 Stock and Incentive Plan, which was amended by Amendment No. 1 thereto (as amended, the "Plan"). The maximum number of Restricted Stock Units ("RSUs") and options issued under the Plan shall not exceed 10% of the issued and outstanding shares on an as-converted basis.

The Company recognizes compensation expense for RSUs and options on a straight-line basis over the requisite service period of the award. Non-market vesting conditions are included in the assumptions about the number of options that are expected to become exercisable. Estimates are subsequently revised if there is any indication that the number of share options expected to vest differs from the previous estimate. Any cumulative adjustment prior to vesting is recognized in the current period with no adjustment to prior periods for expense previously recognized.

Option and RSU awards generally vest over three years, and options typically have a life of five to ten years. Option grants are determined by the Compensation Committee of the Company's Board of Directors with the option price set at no less than 100% of the fair market value of a share on the date of grant.

(Amounts Expressed in United States Dollars, Except Where Stated Otherwise)

## 10. SHARE CAPITAL (Continued)

# (c) Stock-Based Compensation (Continued)

Stock option activity is summarized as follows:

	Number of Shares	Weighted Average Exercise Price C\$	Weighted Average Remaining Contractual Life	Aggregate Intrinsic Value (in thousands)
Balance as of December 31, 2021	5,383,275	18.07	3.59	\$ 48,803
Granted	131,661	26.58	4.81	
Exercised	(109,582)	11.11		1,139
Forfeited	(64,491)			
Balance as of March 31, 2022	5,340,863	18.64	3.28	\$ 42,848
Vested	4,123,521	12.56		
Exercisable of March 31, 2022	2,748,919	12.40	3.07	\$ 29,595

The aggregate intrinsic value in the table above represents the total pre-tax intrinsic value (the difference between the Company's closing stock price on March 31, 2022 and December 31, 2021, respectively, and the exercise price, multiplied by the number of in-the-money options) that would have been received by the option holders had all option holders exercised their in-the-money options on March 31, 2022 and December 31, 2021. This amount will change in future periods based on the fair market value of the Company's Subordinate Voting Shares and the number of options outstanding.

The following table summarizes the weighted average grant date fair value and intrinsic value of options exercised for the three months ended March 31, 2022 and 2021:

	Three Months Ended March 31,		
	2022	2021	
Weighted average grant date fair value (per share) of			
stock option units granted (C\$)	9.57	13.06	
Intrinsic value of stock option units exercised, using			
market price at vest date (US\$) (in thousands)	\$ 1,139	\$ 4,573	

The Company used the Black-Scholes option pricing model to estimate the fair value of the options granted during the three months ended March 31, 2022 and the year ended December 31, 2021, using the following ranges of assumptions:

	March 31,	December 31,
	2022	2021
Risk-free interest rate	1.18% - 1.59%	0.33% - 1.39%
Expected dividend yield	0%	0%
Expected volatility	64%	73%
Expected option life	3.5 years	3-3.5 years

As permitted under ASC 718, the Company has made an accounting policy choice to account for forfeitures when they occur.

# Notes to Unaudited Interim Condensed Consolidated Financial Statements

(Amounts Expressed in United States Dollars, Except Where Stated Otherwise)

# 10. SHARE CAPITAL (Continued)

# (c) Stock-Based Compensation (Continued)

The following table summarizes the number of unvested RSU awards as of March 31, 2022 and December 31, 2021 and the changes during the three months ended March 31, 2022:

	Number of Shares	Weighted Average Grant Date Fair Value (C\$)
Unvested Shares at December 31, 2021	376,127	20.39
Granted	39,742	23.62
Forfeited	(1,500)	19.27
Vested	(107,645)	19.90
Unvested Shares at March 31, 2022	306,724	21.03

The following table summarizes the weighted average grant date fair value of RSUs granted and total fair value of RSUs vested for the three months ended March 31, 2022 and 2021:

	 Three Months Ended March 31,				
	2022	2021			
Weighted average grant date fair value (per share)					
of RSUs granted (C\$)	23.62	39.63			
Intrinsic value of RSUs vested, using market					
price at vest date (US\$) (in thousands)	\$ 2,245 \$	3,106			

The stock-based compensation expense for the three months ended March 31, 2022 and 2021 was as follows:

	Three Months Ended March 31,				
	2022	2021			
\$	3,207 \$	2,629			
	1,444	1,402			
\$	4,651 \$	4,031			
	\$ \$	\$ 3,207 \$ 1,444			

As of March 31, 2022, \$20,251 thousand of total unrecognized expense related to stock-based compensation awards is expected to be recognized over a weighted-average period of 1.91 years.

(Amounts Expressed in United States Dollars, Except Where Stated Otherwise)

# 11. INCOME TAX EXPENSE

The following table summarizes the Company's income tax expense and effective tax rates for the three months ended March 31, 2022 and 2021:

		Three Months Ended March 31,			
		2022	2021		
	(in thousands)				
Income before Income Taxes	\$	60,817 \$	42,311		
Income Tax Expense		31,131	30,856		
Effective Tax Rate		51.2%	72.9%		

The effective tax rates for the three months ended March 31, 2022 and 2021 were based on the Company's forecasted annualized effective tax rates and were adjusted for discrete items that occurred within the periods presented.

Due to its cannabis operations, the Company is subject to the limitations of the U.S. Internal Revenue Code of 1986, as amended ("IRC") Section 280E under which the Company is only allowed to deduct expenses directly related to sales of product. This results in permanent differences between ordinary and necessary business expenses deemed non-allowable under IRC Section 280E. Therefore, the effective tax rate can be highly variable and may not necessarily correlate with pre-tax income and provides for effective tax rates that are well in excess of statutory tax rates.

Taxes paid during the three months ended March 31, 2022 and 2021 were \$132 thousand and \$15,147 thousand, respectively.

#### Notes to Unaudited Interim Condensed Consolidated Financial Statements

(Amounts Expressed in United States Dollars, Except Where Stated Otherwise)

# 12. OTHER INCOME (EXPENSE)

For the three months ended March 31, 2022 and 2021 other income (expense) was comprised of the following:

	Three Months Ended March 31,					
		2022	2021			
		(in thousands)				
Fair value adjustments on equity investments	\$	(9,609) \$	392			
Fair value adjustments on equity method investments		14,119	_			
Fair value adjustments on warrants issued		7,929	(5,851)			
Earnings (loss) from equity method investments		(1,203)	623			
Other		199	(314)			
<b>Total Other Income (Expense)</b>	\$	11,435 \$	(5,150)			

# 13. COMMITMENTS AND CONTINGENCIES

The Company is subject to lawsuits, investigations and other claims related to employment, commercial and other matters that arise out of operations in the normal course of business. Periodically, the Company reviews the status of each significant matter and assesses the potential financial exposure. If the potential loss from any claim or legal proceeding is considered probable, and the amount can be reliably estimated, such amount is recognized in other liabilities.

Contingent liabilities are measured at management's best estimate of the expenditure required to settle the obligation at the end of the reporting period and are discounted to present value where the effect is material. The Company performs evaluations to identify contingent liabilities for contracts. Contingent consideration is measured upon acquisition and is estimated using probability weighting of potential payouts. Subsequent changes in the estimated contingent consideration from the final purchase price allocation are recognized in the Company's unaudited interim condensed consolidated statement of operations.

# (a) Contingencies

The Company's operations are subject to a variety of local and state regulations. Failure to comply with one or more of those regulations could result in fines, sanctions, restrictions on its operations, or losses of permits that could result in the Company ceasing operations in that specific state or local jurisdiction. The Company may be subject to regulatory fines, penalties, or restrictions in the future as cannabis and other regulations continue to evolve and are subject to differing interpretations.

# (b) Claims and Litigation

From time to time, the Company may be involved in litigation relating to claims arising out of operations in the normal course of business. At March 31, 2022 and December 31, 2021, there were no pending or threatened lawsuits that could reasonably be expected to have a material effect on the results of the Company's consolidated operations. There are also no proceedings in which any of the Company's directors, officers or affiliates is an adverse party or has a material interest adverse to the Company's interest.

# (c) Construction Commitments

As of March 31, 2022, the Company held approximately \$75,271 thousand of open construction commitments to contractors on work being performed.

#### Notes to Unaudited Interim Condensed Consolidated Financial Statements

(Amounts Expressed in United States Dollars, Except Where Stated Otherwise)

# 14. FAIR VALUE MEASUREMENTS

The Company applies fair value accounting for all financial assets and liabilities that are recognized or disclosed at fair value in the financial statements on a recurring basis. Fair value is defined as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities that are required to be recorded at fair value, the Company considers all related factors of the asset by market participants in which the Company would transact and the market-based risk measurements or assumptions that market participants would use in pricing the asset or liability, such as inherent risk, transfer restrictions, and credit risk.

The Company applies the following fair value hierarchy, which prioritizes the inputs used to measure fair value into three levels, and bases the categorization within the hierarchy upon the lowest level of input that is available and significant to the fair value measurement:

- Level 1 Unadjusted quoted prices in active markets for identical assets or liabilities;
- Level 2 Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly; and
- Level 3 Inputs for the asset or liability that are not based on observable market data.

# (a) Financial Instruments

The Company's financial instruments consist of cash and cash equivalents, accounts receivable, investments, accounts payable and accrued liabilities, notes payable, warrant liability, and contingent consideration payable.

For the Company's long-term notes payable (which consist of charitable contributions, private placement debt and mortgage notes), for which there were no quoted market prices or active trading markets, it was not practicable to estimate the fair value of these financial instruments. The carrying amount of notes payable at March 31, 2022 and December 31, 2021 was \$244,236 thousand and \$239,934 thousand, which includes \$900 thousand and \$783 thousand, respectively, of short-term debt due within one year.

Financial instruments recorded at fair value are classified using a fair value hierarchy that reflects the significance of the inputs to fair value measurements. The fair values of the Company's financial instruments associated with each of the three levels of the hierarchy are:

	As of March 31, 2022					
		Level 1	Level 2	Level 3	Total	
			(in thousands	)		
Cash and Cash Equivalents	\$	174,539 \$	-\$	— \$	174,539	
Investments		35,784	_	54,947	90,731	
Contingent Consideration Payable		_	_	(55,359)	(55,359)	
Warrant Liability		_	_	(16,948)	(16,948)	
	\$	210,323 \$	<u> </u>	(17,360) \$	192,963	

		As of December 31	1, 2021	
	 Level 1	Level 2	Level 3	Total
		(in thousands)	)	
Cash and Cash Equivalents	\$ 230,420 \$	<b>—</b> \$	<b>— \$</b>	230,420
Investments	44,117	_	50,785	94,902
Contingent Consideration Payable	_	_	(83,865)	(83,865)
Warrant Liability	 		(24,877)	(24,877)
	\$ 274,537 \$	<u> </u>	(57,957) \$	216,580

During the three months ended March 31, 2022, the Company remeasured its contingent consideration arrangements associated with its 2021 acquisitions of Mobley Pain Management and Wellness Center LLC and Canwell Processing LLC (collectively "Summit") and GreenStar Herbals Inc. ("GreenStar") using Monte Carlo simulation models. The remeasurement resulted in a net gain of \$18,979 thousand which was driven by a change in Management's estimates and projections of the acquired entities ability to achieve the performance targets as agreed to in the 2021 acquisition agreements along with the change in fair value of the shares to be issued.

(Amounts Expressed in United States Dollars, Except Where Stated Otherwise)

# 14. FAIR VALUE MEASUREMENTS (Continued)

# (a) Financial Instruments (Continued)

The amount was recorded, net, within selling, general, and administrative expenses on the unaudited interim condensed consolidated statement of operations. Significant assumptions used in the Company's March 31, 2022 remeasurement include Green Thumb's stock price as of March 31, 2022 and projected EBITDA and revenue targets as of such period then ended.

#### Notes to Unaudited Interim Condensed Consolidated Financial Statements

(Amounts Expressed in United States Dollars, Except Where Stated Otherwise)

# 15. VARIABLE INTEREST ENTITIES

The following table presents the summarized financial information about the Company's consolidated variable interest entities ("VIEs") which are included in the unaudited interim condensed consolidated balance sheet as of March 31, 2022 and the consolidated balance sheet as of December 31, 2021. All of these entities were determined to be VIEs as the Company possesses the power to direct activities through management services agreements ("MSAs"):

	_	March 31	, 2022	Decem	ber 31, 2021
			Other		Other
		ILDISP,	Non-material	ILDISP,	Non-material
	_	LLC	VIEs	LLC	VIEs
	_		(in the	ousands)	
Current assets	\$	_ \$	878	\$ 4,118	\$ 1,033
Non-current assets		_	1,743	3,290	1,761
Current liabilities		_	694	10,719	854
Non-current liabilities		_	672	413	696
Noncontrolling interests		_	155	(1,862)	224
Equity attributable to Green Thumb Industries Inc.		_	1,100	(1,862)	1,020

On March 1, 2022, the Company acquired the remaining 50% minority interest in ILDISP, LLC, for \$11,857 thousand in cash and the issuance of 128,218 shares of Green Thumb, which had a fair value of \$2,379 thousand. As a result, the remaining equity associated with the noncontrolling interest was closed to accumulated surplus (deficit) of Green Thumb as of March 1, 2022. See Note 4 - Acquisitions for details.

The following tables present the summarized financial information about the Company's VIEs which are included in the unaudited interim condensed consolidated statements of operations for the three months ended March 31, 2022 and 2021:

	_	<b>Three Months Ended</b>						
		March	March 31, 2022 March			h 3	1, 2021	
			Other				Other	
		ILDISP,		Non-material		ILDISP,		Non-material
		LLC		VIEs		LLC		VIEs
	_			(in th	ous	ands)		
Revenues	\$	3,543	\$	2,266	\$	5,727	\$	3,311
Net income attributable to noncontrolling interests		462		285		783		303
Net income attributable to Green Thumb Industries Inc.		462		241		783		416
Net income	\$	924	\$	526	\$	1,566	\$	719

As of March 31, 2022 and December 31, 2021, the VIE included in the Other Non-material VIEs is Bluepoint Wellness of Westport, LLC. As of March 31, 2021, VIEs included in the Other Non-material VIEs are Bluepoint Wellness of Westport, LLC and Meshow, LLC.

#### Notes to Unaudited Interim Condensed Consolidated Financial Statements

(Amounts Expressed in United States Dollars, Except Where Stated Otherwise)

# 16. SEGMENT REPORTING

The Company operates in two segments: the cultivation, production and sale of cannabis products to retail stores ("Consumer Packaged Goods") and retailing of cannabis to patients and consumers ("Retail"). The Company does not allocate operating expenses to these business units, nor does it allocate specific assets. Additionally, the Chief Operating Decision Maker does not review total assets or net income (loss) by segments; therefore, such information is not presented below.

The below table presents revenues by type for the three months ended March 31, 2022 and 2021:

		Three Months Ended March 31,			
		2022	2021		
		(in thousand	(s)		
Revenues, Net of Discounts					
Consumer Packaged Goods	\$	120,412 \$	104,077		
Retail		172,586	130,109		
Intersegment Eliminations		(50,398)	(39,755)		
Total Revenues, net of discounts	\$	242,600 \$	194,431		
Depreciation and Amortization					
Consumer Packaged Goods	\$	13,157 \$	8,001		
Retail		9,833	6,993		
Intersegment Eliminations		<u></u>			
Total Depreciation and Amortization	\$	22,990 \$	14,994		
Income Taxes	_				
Consumer Packaged Goods	\$	12,941 \$	17,287		
Retail		18,190	13,569		
Intersegment Eliminations		<u> </u>	<u> </u>		
<b>Total Income Taxes</b>	\$	31,131 \$	30,856		

Goodwill assigned to the Consumer Packaged Goods segment as of March 31, 2022 and December 31, 2021 was \$357,871 thousand and \$358,038 thousand, respectively. Intangible assets, net assigned to the Consumer Packaged Goods segment as of March 31, 2022 and December 31, 2021 was \$310,688 thousand and \$317,454 thousand, respectively.

Goodwill assigned to the Retail segment as of March 31, 2022 and December 31, 2021 was \$282,924 thousand and \$274,811 thousand, respectively. Intangible assets, net assigned to the Retail segment as of March 31, 2022 and December 31, 2021 was \$364,004 thousand and \$358,037 thousand, respectively.

The Company's assets are aggregated into two reportable segments (Retail and Consumer Packaged Goods). For the purposes of testing goodwill, Green Thumb has identified 30 reporting units. The Company determined its reporting units by first reviewing the operating segments based on the geographic areas in which Green Thumb conducts business (or each market). The markets were then further divided into reporting units based on the market operations (Retail and Consumer Packaged Goods) which were primarily determined based on the licenses each market holds. All revenues are derived from sales occurring in the United States and all assets are located in the United States.